Navigation Links
Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant
Date:6/4/2008

se infections. Vancomycin is an antibiotic that is often used to treat infections caused by Enterococci. In some instances, Enterococci have become resistant to this drug and thus are called Vancomycin Resistant Enterococci faecalis (VRE).

About Anpath Group, Incorporated:

Anpath Group, Inc., through its wholly owned subsidiary EnviroSystems, Inc., produces cleaning and disinfecting products that it believes will help prevent the spread of infectious microorganisms while minimizing the harmful effects to people, equipment or the environment. Visit http://www.anpathgroup.com for more information.

EnviroSystems, Inc. is focused on safe infection prevention technologies that the company believes will position the company in the forefront of the industry at a time when there is rapidly growing awareness of the critical need to prevent biological risks - both natural and man-made.

Forward Looking Statements:

This release contains forward-looking statements, which reflect expectation or belief by Anpath Group, Inc. concerning future events that involve risks and uncertainties. Anpath Group can give no assurance that the expectations reflected in forward looking statements will prove correct and various factors could cause results to differ materially from Anpath Group expectations, including, but not limited to EPA registration of the Company's products, the Company's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development of its technology, the risk that products may not result from development activities, protection of its intellectual property, need for regulatory approvals, and other factors discussed in periodic Anpath Group, Inc. filings with the Securities and Exchange Commission. Forward-looking statements are qualified in their entirety by the above cautionary statement. Anpath Group assumes no dut
'/>"/>

SOURCE Anpath Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anpath Group, Inc. Announces Selection of its Disinfectant by the Washington Metropolitan Area Transit Authority (Metro)
2. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
3. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
4. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
5. Wound Management Technologies, Inc. Announces Evidence Based Study
6. ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
7. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
8. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
9. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
10. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
11. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... 1 CeloNova BioSciences, Inc., a p...l devices and of specialty implants, today announc...er and medical director of Baptist Cardiac & V...the CATANIA(TM) Stent System with NanoThin Polyzen...erventions Conference to be held at the Hotel Davi...
(Date:12/1/2009)..., Dec. 1 Cumberland Phar...that an independently conducted study of Acetadote...etylcysteine, as a cost-saving treatment for aceta...ber 4 of the peer-reviewed Journal of Medical Eco...ludes that Acetadote is a less costly treatment re...
(Date:12/1/2009)...1 CCS Medical, Inc. a leading dire... announced that it has received approval from the ...aware (the "Court") for its bidding procedures in ... substantially all of its assets. ,, Pursuant t...oved bidding procedures for the sale of substantia...
Breaking Medicine Technology:Dr. Barry Katzen to Present CATANIA(TM) Coronary Stent Data in Tel Aviv 2Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 2Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 3Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 4Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 5Newly Published Acetadote(R) Data Shows Product Can Provide Substantial Cost-Savings for Healthcare Systems 6CCS Medical Wins Approval from Bankruptcy Court for Its Chapter 11 Asset Sale Bidding Procedures 263 percent of RA patients suffer psychiatric disorders with depressive spectrum conditions most likely 48746 163 percent of RA patients suffer psychiatric disorders with depressive spectrum conditions most likely 48746 2Promising device snags young inventors coveted spot at IShow 8813 1Promising device snags young inventors coveted spot at IShow 8813 2Promising device snags young inventors coveted spot at IShow 8813 3Rainforest rehab in every sense 8811 1Rainforest rehab in every sense 8811 2
...ILADELPHIA, Nov. 7 Data from an investigational,o...ing regimens of,PROCRIT(R) (Epoetin alfa) in treat...idney disease (CKD) were presented today at the Am... All three dosing groups, including the FDA-appro...a-week (QW) and,once-every-two-weeks (Q2W) investi...
...N DIEGO, Nov. 6 Cadence Pharmaceuticals,Inc. (Nas...on in-licensing,developing and commercializing pro... the hospital setting, today reported financial re...September 30, 2008., The company also provided an...ts two Phase III product candidates -- Acetavance(...
Other Medicine Technology:Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 2Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 3Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 4Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 5Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 6Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 7Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update 8
(Date:12/2/2009)...ucts Inc., an industry leader in healthcare produc...opening of its new headquarters in the Irvine Spec... Drive, Irvine, California 92618. In addition, Lin...e Spectrum plus an assembly and distribution opera...ion reflects Links Medical,s rapid growth and the ...
(Date:12/2/2009)...ed by Suzanne Somers in her N.Y. Times #1 best-sel... NY (PRWEB) December 2, 2009 -- In her new book KN...cer, And How to Prevent Getting It in the First Pl...cessfully using the most innovative cancer treatme... tear it down. This is a subject Somers writes abo...
(Date:12/2/2009)...vails in counterclaim against three plaintiffs who...ess dispute over work done on hotel construction p...xis Nexis) December 2, 2009 -- The Tampa-based law...ed the settlement of a two-year legal dispute that...t, ConArt, Inc., , ,ConArt, a Georgia-based precas...
(Date:12/2/2009)...eves IBM Ready for LINUX designation and enhances ...nframe and contemporary systems running Linux. , ...er 2, 2009 -- eCube Systems, a leader in legacy ev...nced that it has achieved the IBM Ready for LINUX ...ware. This mark certifies NXTera has met compatib...
(Date:12/2/2009)...PRNewswire/ -- Last month on a prominent nationall...ate Professor at the Stanford Sleep Disorders Clin...mmended the Ecotones Duet Sleep Sound Machine as p...chieve a better night,s sleep with minimal use of ...ople when they are sleeping," said Dr. Pelayo. "Th...
Breaking Medicine News(10 mins):Health News:Links Medical Opens New Headquarters, Prepares to Launch Medical-Grade Manuka Honey 2Health News:Links Medical Opens New Headquarters, Prepares to Launch Medical-Grade Manuka Honey 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 2Health News:Innovative Biofeedback Technology Wins By A "Knockout." 3Health News:Innovative Biofeedback Technology Wins By A "Knockout." 4Health News:Gallagher Keenan Obtains $500,000 Settlement for ConArt, Inc. in Dispute with Florida Hotel Companies 2Health News:eCube Delivers Linux on System z Support for NXTera High Performance Middleware 2Health News:eCube Delivers Linux on System z Support for NXTera High Performance Middleware 3Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 2Health News:Sleep Specialist Dr. Rafael Pelayo Recommends ASTI's Ecotones Duet Sleep Sound Machine 3
...organization analyzed a government survey conducte...n //who had come for having an abortion said they ...d come for repeat abortions were found to be over ...t. Abortions are not uncommon these days and...
...e of drugs such as heroin and crack impacts the ec...?15 billion a year. // These costs were delin...ims, police, court and NHS costs. The European dru... that brown heroin was cheaper by 47% and ecstasy ...
...at, in order to implement better cancer care to pa...tely. //Their views were published in the British ...at the National Institute for Health and Clinical ...to ensure that those battling with cancer shall be...
... Minister for Ageing, Senator Santo Santoro, to di...ies, //as set out in the AMA's Federal Budget Subm...e Medicare Benefits Schedule (MBS) makes it very d...eral practitioners able to visit residential aged ...
...ned to raise its legal age for buying cigarettes f...y said //that the new legislation would go into ef...ollowing the recommendations made by an expert gro...rs and introducing negative licensing law, which w...
...interesting study on longevity. Doctors from the U...n to mothers before they turn 25 were twice more l...kids born to mothers who are older. Researche...mother as well as the order of the birth. The rese...
Other Medicine News:Health News:Cancer Care Compromised by Cost 2
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
...tional reference laboratory and a worldwide leader.... ARUP offers an extensive test menu of highly com...omic pathology. Owned by the University of Utah, A...f the nation's university teaching hospitals and c...
Medicine Products: